28351298|t|Aberrant gene - specific DNA methylation signature analysis in cervical cancer
28351298|a|Multicomponent molecular modifications such as DNA methylation may offer sensitive and specific cervical intraepithelial neoplasia and cervical cancer biomarkers. In this study, we tested cervical tissues at various stages of tumor progression for 5-methylcytosine and 5-hydroxymethylcytosine levels and also DNA promoter methylation profile of a panel of genes for its diagnostic potential. In total, 5-methylcytosine, 5-hydroxymethylcytosine, and promoter methylation of 33 genes were evaluated by reversed-phase high-performance liquid chromatography, enzyme-linked immunosorbent assay based technique, and bisulfate-based next generation sequencing. The 5-methylcytosine and 5-hydroxymethylcytosine contents were significantly reduced in squamous cell carcinoma and receiver operating characteristic curve analysis showed a significant difference in (1) 5-methylcytosine between normal and squamous cell carcinoma tissues (area under the curve = 0.946) and (2) 5-hydroxymethylcytosine levels among normal, squamous intraepithelial lesions and squamous cell carcinoma. Analyses of our next generation sequencing results and data from five independent published studies consisting of 191 normal, 10 low-grade squamous intraepithelial lesions, 21 high-grade squamous intraepithelial lesions, and 335 malignant tissues identified a panel of nine genes (ARHGAP6, DAPK1, HAND2, NKX2-2, NNAT, PCDH10, PROX1, PITX2, and RAB6C) which could effectively discriminate among the various groups with sensitivity and specificity of 80%-100% (p < 0.05). Furthermore, 12 gene promoters (ARHGAP6, HAND2, LHX9, HEY2, NKX2-2, PCDH10, PITX2, PROX1, TBX3, IKBKG, RAB6C, and DAPK1) were also methylated in one or more of the cervical cancer cell lines tested. The global and gene - specific methylation of the panel of genes identified in our study may serve as useful biomarkers for the early detection and clinical management of cervical cancer.
28351298	9	13	gene	T017	UMLS:C0017337
28351298	25	40	DNA methylation	T038	UMLS:C0376452
28351298	51	59	analysis	T062	UMLS:C0936012
28351298	63	78	cervical cancer	T038	UMLS:C4048328
28351298	126	141	DNA methylation	T038	UMLS:C0376452
28351298	175	209	cervical intraepithelial neoplasia	T038	UMLS:C0206708
28351298	214	229	cervical cancer	T038	UMLS:C4048328
28351298	230	240	biomarkers	T103	UMLS:C0041366
28351298	250	255	study	T062	UMLS:C2603343
28351298	267	275	cervical	T082	UMLS:C0027530
28351298	276	283	tissues	T017	UMLS:C0040300
28351298	305	322	tumor progression	T038	UMLS:C0178874
28351298	327	343	5-methylcytosine	T103	UMLS:C0049308
28351298	348	371	5-hydroxymethylcytosine	T103	UMLS:C0049241
28351298	388	391	DNA	T103	UMLS:C0012854
28351298	392	400	promoter	T017	UMLS:C0314621
28351298	401	412	methylation	T038	UMLS:C0376452
28351298	413	420	profile	T058	UMLS:C1979963
28351298	435	440	genes	T017	UMLS:C0017337
28351298	481	497	5-methylcytosine	T103	UMLS:C0049308
28351298	499	522	5-hydroxymethylcytosine	T103	UMLS:C0049241
28351298	528	536	promoter	T017	UMLS:C0314621
28351298	537	548	methylation	T038	UMLS:C0376452
28351298	555	560	genes	T017	UMLS:C0017337
28351298	579	632	reversed-phase high-performance liquid chromatography	T058	UMLS:C0008562
28351298	634	667	enzyme-linked immunosorbent assay	T058	UMLS:C0014441
28351298	689	731	bisulfate-based next generation sequencing	T062	UMLS:C2936622
28351298	737	753	5-methylcytosine	T103	UMLS:C0049308
28351298	758	781	5-hydroxymethylcytosine	T103	UMLS:C0049241
28351298	821	844	squamous cell carcinoma	T038	UMLS:C0007137
28351298	889	897	analysis	T062	UMLS:C0936012
28351298	937	953	5-methylcytosine	T103	UMLS:C0049308
28351298	973	996	squamous cell carcinoma	T038	UMLS:C0007137
28351298	997	1004	tissues	T017	UMLS:C0040300
28351298	1044	1067	5-hydroxymethylcytosine	T103	UMLS:C0049241
28351298	1081	1087	normal	T033	UMLS:C0221198
28351298	1089	1121	squamous intraepithelial lesions	T038	UMLS:C0333873
28351298	1126	1149	squamous cell carcinoma	T038	UMLS:C0007137
28351298	1151	1159	Analyses	T062	UMLS:C0936012
28351298	1167	1193	next generation sequencing	T062	UMLS:C2936622
28351298	1233	1250	published studies	T170	UMLS:C1704324
28351298	1269	1275	normal	T033	UMLS:C0221198
28351298	1280	1322	low-grade squamous intraepithelial lesions	T038	UMLS:C1302773
28351298	1327	1370	high-grade squamous intraepithelial lesions	T038	UMLS:C0333875
28351298	1380	1389	malignant	T038	UMLS:C0006826
28351298	1390	1397	tissues	T017	UMLS:C0040300
28351298	1425	1430	genes	T017	UMLS:C0017337
28351298	1432	1439	ARHGAP6	T017	UMLS:C1412523
28351298	1441	1446	DAPK1	T017	UMLS:C1413906
28351298	1448	1453	HAND2	T017	UMLS:C1415467
28351298	1455	1461	NKX2-2	T017	UMLS:C1417735
28351298	1463	1467	NNAT	T017	UMLS:C1417747
28351298	1469	1475	PCDH10	T017	UMLS:C1421975
28351298	1477	1482	PROX1	T017	UMLS:C1418951
28351298	1484	1489	PITX2	T017	UMLS:C1418596
28351298	1495	1500	RAB6C	T017	UMLS:C1424353
28351298	1637	1651	gene promoters	T017	UMLS:C0314621
28351298	1653	1660	ARHGAP6	T017	UMLS:C1412523
28351298	1662	1667	HAND2	T017	UMLS:C1415467
28351298	1669	1673	LHX9	T017	UMLS:C1422495
28351298	1675	1679	HEY2	T017	UMLS:C1415525
28351298	1681	1687	NKX2-2	T017	UMLS:C1417735
28351298	1689	1695	PCDH10	T017	UMLS:C1421975
28351298	1697	1702	PITX2	T017	UMLS:C1418596
28351298	1704	1709	PROX1	T017	UMLS:C1418951
28351298	1711	1715	TBX3	T017	UMLS:C1420613
28351298	1717	1722	IKBKG	T017	UMLS:C1416380
28351298	1724	1729	RAB6C	T017	UMLS:C1424353
28351298	1735	1740	DAPK1	T017	UMLS:C1413906
28351298	1752	1762	methylated	T038	UMLS:C0376452
28351298	1785	1800	cervical cancer	T038	UMLS:C4048328
28351298	1801	1811	cell lines	T017	UMLS:C0007600
28351298	1835	1839	gene	T017	UMLS:C0017337
28351298	1851	1862	methylation	T038	UMLS:C0376452
28351298	1879	1884	genes	T017	UMLS:C0017337
28351298	1903	1908	study	T062	UMLS:C2603343
28351298	1929	1939	biomarkers	T103	UMLS:C0041366
28351298	1954	1963	detection	T058	UMLS:C1511790
28351298	1968	1987	clinical management	T058	UMLS:C1516615
28351298	1991	2006	cervical cancer	T038	UMLS:C4048328